Novel immunosuppressive agents in kidney transplantation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Dec 24, 2013; 3(4): 68-77
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.68

Table 2 Non-Food and Drug Administration approved/investigational agents and their mechanism

Drug name	Mechanism of action
Induction
Efalizumab¹	Humanized antibody, CD11a/LFA-1
Alefacept¹	Costimulation inhibitor, CD2 LFA3
Maintenance
Voclosporin, ISA247	Calcineurin inhibitor
Sotrastaurin, AEB0711	Protein kinase C inhibitor
Tofacitinib, CP-6905501	JAK 3 inhibitor
ASKP1240	Anti-CD40 monoclonal antibody
Treatment of Antibody Medicated Rejection
Bortezomib	Proteasome inhibitor
Eculizumab	Monoclonal antibody, C5 complement protein

¹No longer being investigated for transplantation.

Citation: Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77
URL: https://www.wjgnet.com/2220-3230/full/v3/i4/68.htm
DOI: https://dx.doi.org/10.5500/wjt.v3.i4.68

Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77 [PMID: 24392311 DOI: 10.5500/wjt.v3.i4.68]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.